

Summary

In a first aspect of the present disclosure, there is provided a compound of the formula:




wherein R is H or



;

R^1 is H, halogen, CN, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF_3,



R^2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C3 alkenyl;

R^3 is NH_2, or CH_2NH_2; and

X is O, OCH_2, OCH_2CH_2, CH_2O, SCH_2, CH_2S, CH_2, $NHCH_2$, CH_2NH, $N(CH_3)CH_2$, CH_2CH_2, C≡C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof.

In another aspect of the present disclosure, there is provided a use of a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating atopic dermatitis in a patient.

In yet another aspect of the present disclosure, there is provided a use of a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating rheumatoid arthritis in a patient.

In a further aspect of the present disclosure, there is provided a compound or pharmaceutically acceptable salt thereof as disclosed herein, for use in therapy.

In another aspect of the present disclosure, there is provided a compound or pharmaceutically acceptable salt thereof as disclosed herein, for use in treating atopic dermatitis.


In yet another aspect of the present disclosure, there is provided a compound or pharmaceutically acceptable salt thereof as disclosed herein, for use in treating rheumatoid arthritis.

In a further aspect of the present disclosure, there is provided a pharmaceutical composition, comprising a compound or a pharmaceutically acceptable salt thereof, as disclosed herein with one or more pharmaceutically acceptable carriers, diluents, or excipients.

In another aspect of the present disclosure, there is provided a process for preparing a pharmaceutical composition, comprising admixing a compound or a pharmaceutically acceptable salt thereof as disclosed herein with one or more pharmaceutically acceptable carriers, diluents, or excipients.


Description

Accordingly, in one embodiment, the invention provides a compound of Formula I:




Formula I

wherein R is H or



;

R^1 is H, halogen, CN, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF_3,




R^2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C3 alkenyl;

R^3 is NH_2, or CH_2NH_2; and


X is O, OCH_2, OCH_2CH_2, CH_2O, SCH_2, CH_2S, CH_2, $NHCH_2$, CH_2NH, $N(CH_3)CH_2$, CH_2CH_2, C≡C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof.

WHAT IS CLAIMED IS:

1. A compound of the formula:




wherein R is H or



;

R^1 is H, halogen, CN, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF_3,



;

R^2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C3 alkenyl;


R^3 is NH_2, or CH_2NH_2; and

X is O, OCH_2, OCH_2CH_2, CH_2O, SCH_2, CH_2S, CH_2, $NHCH_2$, CH_2NH, $N(CH_3)CH_2$, CH_2CH_2, C≡C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 wherein R^3 is NH_2, or a pharmaceutically acceptable salt thereof.

3. The compound according to either claim 1 or claim 2 wherein R is H, or a pharmaceutically acceptable salt thereof.

4. The compound according to either claim 1 or claim 2 wherein R is



,

or a pharmaceutically acceptable salt thereof.

5. The compound according to any one of claims 1-4 wherein R^1 is C1-C3 alkyl, or a pharmaceutically acceptable salt thereof.

6. The compound according to any one of claims 1-4 wherein R^1 is CH_3, or a pharmaceutically acceptable salt thereof.

7. The compound according to any one of claims 1-4 wherein R^1 is C1-C3 alkoxy, or a pharmaceutically acceptable salt thereof.

8. The compound according to any one of claims 1-4 wherein R^1 is OCH_3, or a pharmaceutically acceptable salt thereof.

9. The compound according to any one of claims 1-4 wherein R^1 is F, or a pharmaceutically acceptable salt thereof.

10. The compound according to any one of claims 1-9 wherein R^2 is F, or a pharmaceutically acceptable salt thereof.

11. The compound according to any one of claims 1-10 wherein X is OCH_2, or a pharmaceutically acceptable salt thereof.


12. The compound according to any one of claims 1-10 wherein X is O, or a pharmaceutically acceptable salt thereof.

13. The compound according to any one of claims 1-10 wherein X is CH_2, or a pharmaceutically acceptable salt thereof.

14. The compound according to any one of claims 1-10 wherein X is SCH_2, or a pharmaceutically acceptable salt thereof.

15. The compound according to any one of claims 1-10 wherein X is a bond, or a pharmaceutically acceptable salt thereof.


16. The compound according to claims 1 wherein the compound is of the formula:



,

or a pharmaceuticall acceptable salt thereof.


17. The compound according to claim 1 wherein the compound is of the formula:



,

or a pharmaceuticall acceptable salt thereof.


18. The compound according to claim 17 wherein the compound is:



,


or a pharmaceutically acceptable salt thereof.

19. The compound according to claim 18 which is:



.


20. The compound according to claim 1 wherein the compound is:



,


or a pharmaceutically acceptable salt thereof.

21. The compound according to claim 20, which is:



.


22. The compound according to claim 16 wherein the compound is:



,


or a pharmaceutically acceptable salt thereof.

23. The compound according to claim 22 which is:



.


24. The compound according to claim 1 wherein the compound is:



,


or a pharmaceutically acceptable salt thereof.

25. The compound according to claim 24 which is:



.


26. The compound according to claim 1 wherein the compound is:



,


or a pharmaceutically acceptable salt thereof.

27. The compound according to claim 26 which is:



.


28. The compound according to claim 1 wherein the compound is:



,



or a pharmaceutically acceptable salt thereof.








29. The compound according to claim 28 which is:

















.








30. The compound according to claim 1 selected from the group consisting of:







1	
2	








3	
4	
5	
6	
7	
8	
9	








10	
11	
12	
13	
14	
15	
16	
17	








18	
19	
20	
21	
22	
23	








24	
25	
26	
27	
28	
29	
30	








31	
32	
33	
34	
35	
36	








37	
38	
39	
40	
41	
42	
43	









44	
45	
46	
47	
48	
49	
50	








51	
52	
53	
54	
55	
56	
57	









58	
59	
60	
61	
62	
63	
64	









65	
66	
67	
68	
69	
70	
71	








72	
73	
74	
75	
76	
77	
78	








79	
80	
81	
82	
83	
84	
85	
86	







87	
88	
89	
90	
91	
92	
93	








94	
95	
96	
97	
98	
99	
100	
101	








102	
103	
104	
105	
106	
107	
108	
109	








110	
111	
112	
113	
114	
115	
116	









117	
118	
119	
120	
121	
122	
123	


124	
125	
126	
127	
128	
129	

130	
131	
132	
133	
134	
135	
136	

137	
138	
139	
140	
141	
142	
143	

144	
145	
146	
147	
148	
149	
150	

151	
152	
153	
154	
155	
156	
157	
158	 ; and

159	

;

and pharmaceutically acceptable salts thereof.

31. Use of a compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating atopic dermatitis in a patient.

32. Use of a compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating rheumatoid arthritis in a patient.

33. A compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 30, for use in therapy.

34. A compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 30, for use in treating atopic dermatitis.

35. A compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 30, for use in treating rheumatoid arthritis.

36. A pharmaceutical composition, comprising a compound or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 30 with one or more pharmaceutically acceptable carriers, diluents, or excipients.

37. A process for preparing a pharmaceutical composition, comprising admixing a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 30 with one or more pharmaceutically acceptable carriers, diluents, or excipients.